210results about How to "Low effective dose" patented technology

The present invention is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The invention discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.

The present invention relates to control of pest infestation by inhibiting one or more biological functions. The invention provides methods and compositions for such control. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the pest, a reduction in pest infestation is obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.

The present invention provides combination therapies for treating a disease, disorder, or condition, and methods thereof.

The invention is intended for a treatment of severe infections using an injectable drug-delivery system comprising nanoparticles of a biodegradable polymer with incorporated antibacterial drug.

A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.

The present invention relates to methods for intradermally delivering one or more biologically active agents such as vaccines and therapeutic agents into the dermis layer of the skin of a subject to obtain systemic delivery or an immune response using a microneedle drug delivery device containing the agent to be delivered. The methods employ a microneedle device with a row of hollow microneedles. The microneedles penetrate the skin of the subject and assume an anchored state in which the microneedles are anchored in the skin and project laterally from the device. A pivotal motion is then performed with the device so that the skin in which the microneedles are engaged is lifted above the initial plane of the surface of the skin while the biologically active agent is delivered. The methods of the invention elicit increased humoral and / or cellular response as compared to conventional vaccine delivery routes, facilitating dose sparing.

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.

Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.

A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.

ACE-2 inhibiting compounds are disclosed. These compounds include compounds of formula (IV):wherein the variables are as described in the specification. Pharmaceutical compositions containing the compounds are also discussed. The pharmaceutical compositions may contain an effective amount of a compound of the invention to treat ACE-2 associated disorders such as a blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder.< / PTEXT>

The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.

A bioresorbable material is incorporated with bioactive agents to form an implant used for treatment against hard tissue or soft tissue defects and diseases. Antibiotics or anti-cancer agents are incorporated to treat hard or soft tissue infections or cancers. Sustained release of the bioactive agents or drug molecules may be achieved after implantation at the targeted sites. The dosage of the active agents or molecules, the microstructure, morphology, and composition of the bioresorbable material allow control of the release profile. The invented implant may be used for drug delivery, chemotherapy, or gene therapy. Various microstructure and the morphologies of the implants are injectable like putty or shaped with multilayers.

The present invention relates to American goldenrod herb total flavone extract and its preparation process and use. The American goldenrod herb total flavone extract contains quercetin, quercetin-3-O-beta-D-heteroside, kaempferol-3-O-alpha-L-rhamnoside, chlorogenic acid, etc. capable of preventing and treating senile dementia, various inflammatory respiratory diseases, esophagus cancer, etc. The preparation process is simple, high extracting rate, and the extract has high pharmacological effect, stable property, low toxicity and controllable quality.

The invention relates to a new and improved pharmaceutical composition and method for delivery of therapeutic agents. The methods and composition of the invention can be used with several therapeutic agents and can achieve site specific delivery of a therapeutic or diagnostic substance. This can allow for lower doses and for improved efficacy with drugs which traditionally reach targeted sites and can result in improved utility for agents such as oligonucleotides and polynucleotides which are plagued with problems with biodistribution.

This invention relates to a novel immunoadjuvant, an adjuvant component, and vaccines containing the adjuvant component. The adjuvant includes phytol or a phytol derivative. The adjuvant component, when combined with a soluble or particulate antigen, provides a vaccine with an enhanced ability to induce both humoral and cytotoxic immune responses while displaying reduced toxicity and / or adverse side effects over vaccines that include the antigen but without the benefit of this adjuvant component.

A decoy inactive carrier composition is administered simultaneously with a targeted composition containing vehicles for delivering a desired agent to a biological target. This simultaneous administration enhances the delivery of the targeted composition to the desired location in a subject.

The present invention is directed to a powdered formulation comprising an analgesic, preferably fentanyl, for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as well as effective analgesic amounts of fentanyl in a shorter time and at lower dose levels of administered fentanyl when compared to fentanyl administered by an oral transmucosal route.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

The present invention relates to a new-type high-effective safety medicine-ginkgo leaf total lactone for curing depression. It is a terpene lactone extracted from ginkgo biloba. L or other portions of said plant, such as ginkgo nut, ginkgo root bark and ginkgo twing, in which five terpene lactone compounds of bilobalide A, bilobalide B, bilobalide C, bilobalide J and bilobalide are mainly contained.

A Chinese medicine for treating diabetes and nephrosis is prepared from 4 Chinese-medicinal materials including astragalus root, rhubarb, etc.

An application of the casticin extracted from shrub chastetree fruit in preparing the medicines for preventing, diagnosing and treating premenstrual syndrome is disclosed.

The present invention relates to novel human coagulation Factor VII / VIIa proteins having coagulant potential / activity as well as pharmaceutical compositions comprising the polypeptides, uses and methods of treatment. In particular, the present invention relates to novel, semi synthetic analogues of human coagulation Factor VII and VIIa (FVII and FVIIa) as well as to a method of their production.

The invention relates to a Chinese traditional medicine extract for preventing and treating osteoporosis and its preparation method and application. The extract mainly comprises rhizoma atractylodis volatile oil, total alkaloid of Phellodendron amurense, and total saponins of radix achyranthis bidentatae and total sterone of radix achyranthis bidentatae; can be used for preventing and / or treating osteoporosis and relevant disorder, which has gradually become important pathogenesis influencing life-quality. The extract has easily-accessible raw materials, simple preparation, high extraction efficiency, strong pharmacological action, stable quality, high safety, low toxicity, and controllable quality. The invention comprises three Chinese traditional medicines in classical prescription, come to optima activity for resisting osteoporosis, reduces adverse side effect, and provides a new medicament source for preventing, diagnostic ting, detecting, protecting, treating and researching these diseases and their relevant diseases.

The invention discloses an alpha-MSH analogue AC-Nle-cyclo(-Asp-His-D-Phe-Arg-Trg-Lys)-OH(SEQ ID No:1) polypeptide and derivative (SEQ ID No:2) whose C end is umidated for curing sexual dysfunction, and discloses a method for synthesizing the above-mentioned polypeptide, and discloses a medicine composite containing the above-mentioned polypeptide for curing sexual dysfunction and its preparation method, and application of said medicine composite for curing sexual dysfunction diseases, including male sexual dysfunction, for example, erectile dysfunction and female sexual dysfunction.

Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.

The invention provides a honeysuckle extract and a preparation method for extracting chlorogenci acid. The method has the advantages of good repeatability and good stability; by using the method, the content of an active component can be improved, a large amount of impurities are removed, raw materials are high in yield and low in cost; and the method is suitable for industrial production. The percentage of the main active component chlorogenci acid in the honeysuckle extract is 30%. The preparation process of the honeysuckle extract comprises the following steps: adding water the volume of which is 8-20 times as large as that of taken honeysuckle medicinal material in the taken honeysuckle medicinal to extract for 2-4 times for 0.5-1.5 hours each time; regulating the pH value of the extract to 1-6; and on a large pore absorption resin column, eluting impurities with water firstly, then eluting with 10-70% ethanol, colleting ethanol eluent, recovering the ethanol, concentrating, regulating the pH value of a concentrated liquid to 1-6, adding ethyl acetate for extraction, recovering the ethyl acetate, concentrating and drying. By using the method, the content of the active component in the extract is improved, the curative effect is improved, a large amount of impurities are removed, the problem of large moisture absorption commonly occurring in Chinese patent medicines is solved, and side effects are reduced.